IHC revealed moderate-to-strong CD73 expression in IDH-wildtype and IDH-mutant adult glioblastomas, H3K27M-mutant diffuse midline gliomas, and pediatric HGG, as well as oligodendrogliomas, pilocytic astrocytomas, meningiomas, and papillary craniopharyngiomas (Fig. 4B–D; Fig. S6; Supplementary Data 6–10). This evidence concerns the gene NT5E and meningioma.